Foxhaven Asset Management’s Affirm AFRM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$125M Sell
1,534,155
-671,401
-30% -$43.9M 3.35% 12
2026
Q1
$101M Buy
2,205,556
+298,674
+16% +$17.3M 3.17% 13
2025
Q4
$142M Sell
1,906,882
-25,599
-1% -$1.84M 3.5% 11
2025
Q3
$141M Sell
1,932,481
-964,427
-33% -$73.4M 3.25% 14
2025
Q2
$200M Buy
2,896,908
+814,951
+39% +$42.3M 4.83% 9
2025
Q1
$94.1M Buy
2,081,957
+753,273
+57% +$44.6M 2.86% 15
2024
Q4
$80.9M Buy
+1,328,684
New +$73.9M 2.17% 15
2023
Q2
Sell
-200,000
Closed -$2.25M 24
2023
Q1
$2.25M Hold
200,000
0.08% 25
2022
Q4
$1.93M Hold
200,000
0.08% 25
2022
Q3
$3.75M Hold
200,000
0.17% 24
2022
Q2
$3.61M Hold
200,000
0.16% 20
2022
Q1
$9.26M Hold
200,000
0.34% 18
2021
Q4
$20.1M Hold
200,000
0.58% 19
2021
Q3
$23.8M Hold
200,000
0.69% 19
2021
Q2
$13.5M Hold
200,000
0.37% 21
2021
Q1
$14.1M Buy
+200,000
New +$19.4M 0.41% 22

Other funds holding AFRM

Foxhaven Asset Management's AFRM Position: Q2 2026 in Review

Foxhaven Asset Management reduced its Affirm (AFRM) stake by 30% in Q2 2026, selling an estimated $43.9M and leaving 1,534,155 shares worth $125M. The position accounts for 3.35% of the portfolio, ranked #12.

Foxhaven Asset Management first reported a position in AFRM in Q1 2021 and has held it in 16 quarters since. The position peaked at $200M in Q2 2025. 659 funds tracked by Wall St. Rank hold AFRM as of Q2 2026.

  • Foxhaven Asset Management held 1,534,155 shares of Affirm worth $125M as of Q2 2026.
  • Foxhaven Asset Management sold 671,401 Affirm shares in Q2 2026, an estimated $43.9M.
  • Affirm made up 3.35% of Foxhaven Asset Management's portfolio in Q2 2026, its #12 holding.
  • Foxhaven Asset Management first reported a position in Affirm in Q1 2021 and has held it in 16 quarters since.
  • Foxhaven Asset Management's Affirm position peaked at $200M in Q2 2025.
  • 659 funds tracked by Wall St. Rank held Affirm as of Q2 2026.

Based on Foxhaven Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.